HK1139855A1 - Specific 3-heteroaryl-3-hydroxy-2-amino-propionic acid amide derivative for use in the treatment of certain cognitive disorders - Google Patents
Specific 3-heteroaryl-3-hydroxy-2-amino-propionic acid amide derivative for use in the treatment of certain cognitive disordersInfo
- Publication number
- HK1139855A1 HK1139855A1 HK10105998.9A HK10105998A HK1139855A1 HK 1139855 A1 HK1139855 A1 HK 1139855A1 HK 10105998 A HK10105998 A HK 10105998A HK 1139855 A1 HK1139855 A1 HK 1139855A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- heteroaryl
- hydroxy
- amino
- treatment
- specific
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Quinoline Compounds (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89319607P | 2007-03-06 | 2007-03-06 | |
| PCT/US2008/055812 WO2008109610A1 (en) | 2007-03-06 | 2008-03-04 | Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1139855A1 true HK1139855A1 (en) | 2010-09-30 |
Family
ID=39535350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK10105998.9A HK1139855A1 (en) | 2007-03-06 | 2010-06-15 | Specific 3-heteroaryl-3-hydroxy-2-amino-propionic acid amide derivative for use in the treatment of certain cognitive disorders |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8623891B2 (de) |
| EP (2) | EP2481407B1 (de) |
| JP (1) | JP2010520299A (de) |
| AU (3) | AU2008222890C1 (de) |
| BR (1) | BRPI0808353B8 (de) |
| CA (1) | CA2680324A1 (de) |
| DK (1) | DK2481407T3 (de) |
| ES (2) | ES2711075T3 (de) |
| HK (1) | HK1139855A1 (de) |
| PT (1) | PT2481407T (de) |
| TR (1) | TR201818771T4 (de) |
| WO (1) | WO2008109610A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1841756B1 (de) * | 2005-01-26 | 2011-09-07 | Allergan, Inc. | 3-heterocyclyl-3-hydroxy-2-amino-propionsäure-amide und damit zusammenhängende verbindungen mit analgesischer und/oder immunostimulatorischer aktivität |
| NZ582874A (en) * | 2007-07-17 | 2012-06-29 | Allergan Inc | Methods for treating anxiety |
| CA2768356A1 (en) * | 2009-07-17 | 2011-01-20 | Allergan, Inc. | Compositions comprising a cholinesterase inhibitor for treating cognitive disorders |
| CA2774355A1 (en) | 2009-09-16 | 2011-03-24 | Allergan, Inc. | Compositions and methods for treating spasticity |
| WO2011034915A1 (en) * | 2009-09-16 | 2011-03-24 | Allergan, Inc. | Compositions and methods for treating disorders of gastrointestinal motility |
| US8242141B2 (en) * | 2009-09-16 | 2012-08-14 | Allergan, Inc. | Compositions and methods for treating seizure disorders |
| PT3033327T (pt) * | 2013-08-15 | 2018-04-04 | Allergan Inc | L)-(+) tartarato de (-)-(2r,3s)-2-amino-3hidroxi-3-piridin-4-il-1-pirrolidin-1-il-propan-1-ona, seus métodos de produção e utilização |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62114946A (ja) | 1985-11-13 | 1987-05-26 | Banyu Pharmaceut Co Ltd | フエニルセリンアミド誘導体およびそれを有効成分とする中枢神経系用剤 |
| WO1997010817A1 (en) | 1995-09-20 | 1997-03-27 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| NO965193L (no) * | 1995-12-08 | 1997-06-09 | Seikagaku Kogyo Kk Seikagaku C | Aminalkoholderivat og fremgangsmåte for fremstilling derav |
| GB9909064D0 (en) * | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
| SE9904197D0 (sv) | 1999-11-22 | 1999-11-22 | Amersham Pharm Biotech Ab | A method for anion exchange adsorption on matrices carrying mixed mode ligands |
| JP5038582B2 (ja) * | 2001-07-16 | 2012-10-03 | ジェンザイム・コーポレーション | Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成 |
| WO2003045928A1 (en) * | 2001-11-26 | 2003-06-05 | Genzyme Corporation | Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors |
| US20050101674A1 (en) * | 2003-11-12 | 2005-05-12 | Maurer Barry J. | PPMP as a ceramide catabolism inhibitor for cancer treatment |
| US20060081273A1 (en) * | 2004-10-20 | 2006-04-20 | Mcdermott Wayne T | Dense fluid compositions and processes using same for article treatment and residue removal |
| EP1841756B1 (de) | 2005-01-26 | 2011-09-07 | Allergan, Inc. | 3-heterocyclyl-3-hydroxy-2-amino-propionsäure-amide und damit zusammenhängende verbindungen mit analgesischer und/oder immunostimulatorischer aktivität |
| WO2008011485A2 (en) | 2006-07-19 | 2008-01-24 | Allergan, Inc. | Methods for treating chronic pain |
| WO2008011483A2 (en) | 2006-07-19 | 2008-01-24 | Allergan, Inc. | Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds |
-
2008
- 2008-03-04 ES ES12151551T patent/ES2711075T3/es active Active
- 2008-03-04 AU AU2008222890A patent/AU2008222890C1/en active Active
- 2008-03-04 EP EP12151551.4A patent/EP2481407B1/de active Active
- 2008-03-04 PT PT12151551T patent/PT2481407T/pt unknown
- 2008-03-04 CA CA002680324A patent/CA2680324A1/en not_active Abandoned
- 2008-03-04 TR TR2018/18771T patent/TR201818771T4/tr unknown
- 2008-03-04 JP JP2009552838A patent/JP2010520299A/ja active Pending
- 2008-03-04 WO PCT/US2008/055812 patent/WO2008109610A1/en active Application Filing
- 2008-03-04 BR BRPI0808353A patent/BRPI0808353B8/pt active IP Right Grant
- 2008-03-04 DK DK12151551.4T patent/DK2481407T3/en active
- 2008-03-04 ES ES08731362T patent/ES2383384T3/es active Active
- 2008-03-04 EP EP08731362A patent/EP2131837B1/de active Active
- 2008-03-04 US US12/530,124 patent/US8623891B2/en active Active
-
2010
- 2010-06-15 HK HK10105998.9A patent/HK1139855A1/xx not_active IP Right Cessation
-
2016
- 2016-06-24 AU AU2016204334A patent/AU2016204334B2/en active Active
-
2018
- 2018-06-15 AU AU2018204290A patent/AU2018204290B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2383384T3 (es) | 2012-06-20 |
| AU2018204290B2 (en) | 2020-05-21 |
| US20100093793A1 (en) | 2010-04-15 |
| CA2680324A1 (en) | 2008-09-12 |
| WO2008109610A1 (en) | 2008-09-12 |
| EP2131837B1 (de) | 2012-05-16 |
| AU2008222890B2 (en) | 2016-03-31 |
| AU2008222890C1 (en) | 2016-09-08 |
| EP2481407B1 (de) | 2018-09-26 |
| JP2010520299A (ja) | 2010-06-10 |
| TR201818771T4 (tr) | 2019-01-21 |
| EP2131837A1 (de) | 2009-12-16 |
| AU2016204334A1 (en) | 2016-07-14 |
| BRPI0808353B8 (pt) | 2021-05-25 |
| DK2481407T3 (en) | 2019-01-07 |
| BRPI0808353B1 (pt) | 2020-03-31 |
| ES2711075T3 (es) | 2019-04-30 |
| BRPI0808353A2 (pt) | 2014-07-29 |
| AU2018204290A1 (en) | 2018-07-05 |
| AU2016204334B2 (en) | 2018-03-15 |
| AU2008222890A1 (en) | 2008-09-12 |
| PT2481407T (pt) | 2018-12-28 |
| US8623891B2 (en) | 2014-01-07 |
| EP2481407A1 (de) | 2012-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL195906A0 (en) | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | |
| ZA201100482B (en) | Pyrazolopyrimidines and their use for the treatment of cns disorders | |
| GB201001047D0 (en) | Methods and compositions for the treatment of neurological disorders | |
| EP2268140A4 (de) | Neue verbindungen, die vorteilhaft für die behandlung von erkrankungen und störungen des zentralnervensystems sind | |
| EP2166837A4 (de) | Wirkstoffkombination zur behandlung von hauterkrankungen | |
| HK1158172A1 (en) | Compounds for treating ophthalmic diseases and disorders | |
| GB0703909D0 (en) | Treatment of anxiety disorders | |
| HK1152939A1 (en) | Carboxamide compounds for the treatment of metabolic disorders | |
| EP2278972A4 (de) | Behandlung für neurologische und psychische erkrankungen | |
| SI2137141T1 (sl) | Arilamidi bifenil-4-il-sulfonske kisline in njihova uporaba kot terapevtska sredstva | |
| HK1139855A1 (en) | Specific 3-heteroaryl-3-hydroxy-2-amino-propionic acid amide derivative for use in the treatment of certain cognitive disorders | |
| IL205578A0 (en) | Aldh-2 inhibitors in the treatment of psychiatric disorders | |
| GB0915259D0 (en) | Sulphur-linked compounds for treating ophthalmic diseases and disorders | |
| ZA200806455B (en) | Use of 2-imidazoles for the treatment of CNS disorders | |
| AU2008233088A8 (en) | Calcimimetic compounds for use in the treatment of bowel disorders | |
| HK1134032A1 (en) | New combination for use in the treatment of inflammatory disorders | |
| IL192877A0 (en) | Use of 2-imidazoles for the treatment of cns disorders | |
| IL209417A0 (en) | 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders | |
| EP2099444A4 (de) | Verwendung von d-serin-derivaten zur behandlung von angststörungen | |
| PL1982178T3 (pl) | Sposoby leczenia zaburzeń afektywnych | |
| IL193943A0 (en) | The use of beta- aminoalcohols for the treatment of inflammatory disorders and pain | |
| PT2278962E (pt) | Métodos para o tratamento de desordens dermatológicas | |
| IL210558A0 (en) | Treatment of anxiety disorders | |
| EP2212246B1 (de) | Behandlung von neurologischen störungen | |
| IL193944A0 (en) | The use beta-aminoalcohols for the treatment of inflammatory disorders and pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20160304 |